CR20220279A - Análogos de incretina y sus usos - Google Patents

Análogos de incretina y sus usos

Info

Publication number
CR20220279A
CR20220279A CR20220279A CR20220279A CR20220279A CR 20220279 A CR20220279 A CR 20220279A CR 20220279 A CR20220279 A CR 20220279A CR 20220279 A CR20220279 A CR 20220279A CR 20220279 A CR20220279 A CR 20220279A
Authority
CR
Costa Rica
Prior art keywords
incretin analogs
glucagon
receptors
activity
incretin
Prior art date
Application number
CR20220279A
Other languages
English (en)
Inventor
Tamer Coskun
Hongchang Qu
Milata Mary Abraham
Jorge Alsina-Fernandez
James Lincoln Wallis
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20220279A publication Critical patent/CR20220279A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Details Of Garments (AREA)

Abstract

Se proporcionan los análogos de incretina que tienen actividad en cada uno de los receptores del polipéptido insulinotrópico dependiente de glucosa (GIP), el péptido similar a glucagón-1 (GLP-1) y el glucagón (GCG). Los análogos de incretina tienen características estructurales que dan como resultado una actividad equilibrada y una duración de acción extendida en cada uno de estos receptores. También se proporcionan los métodos para tratar las enfermedades, tales como la diabetes mellitus tipo 2, la dislipidemia, el síndrome metabólico, la enfermedad del hígado graso no alcohólico, la esteatohepatitis no alcohólica y la obesidad.
CR20220279A 2019-12-18 2020-12-11 Análogos de incretina y sus usos CR20220279A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962949661P 2019-12-18 2019-12-18
PCT/US2020/064512 WO2021126695A1 (en) 2019-12-18 2020-12-11 Incretin analogs and uses thereof

Publications (1)

Publication Number Publication Date
CR20220279A true CR20220279A (es) 2022-07-03

Family

ID=74181298

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220279A CR20220279A (es) 2019-12-18 2020-12-11 Análogos de incretina y sus usos

Country Status (20)

Country Link
US (1) US20230102339A1 (es)
EP (1) EP4077365A1 (es)
JP (1) JP7450724B2 (es)
KR (1) KR20220100676A (es)
CN (1) CN114787183A (es)
AR (1) AR120714A1 (es)
AU (1) AU2020408139B2 (es)
BR (1) BR112022009396A2 (es)
CA (1) CA3162245A1 (es)
CL (1) CL2022001623A1 (es)
CO (1) CO2022008264A2 (es)
CR (1) CR20220279A (es)
DO (1) DOP2022000122A (es)
EC (1) ECSP22048612A (es)
IL (1) IL293754A (es)
JO (1) JOP20220153A1 (es)
MX (1) MX2022007666A (es)
PE (1) PE20221518A1 (es)
TW (1) TWI795698B (es)
WO (1) WO2021126695A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023008330A (es) 2021-01-20 2024-01-18 Viking Therapeutics Inc Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
WO2023088140A1 (zh) * 2021-11-19 2023-05-25 南京明德新药研发有限公司 订合肽及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
BR112016009995B1 (pt) 2013-11-06 2023-04-18 Zealand Pharma A/S Compostos agonistas triplos glucagon-glp-1-gip
WO2015095684A1 (en) 2013-12-20 2015-06-25 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TN2018000231A1 (en) 2015-12-31 2019-10-04 Hanmi Pharm Ind Co Ltd Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
SG11201806342SA (en) 2016-03-10 2018-08-30 Medimmune Ltd Glucagon and glp-1 co-agonists for the treatment of obesity
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途

Also Published As

Publication number Publication date
JP7450724B2 (ja) 2024-03-15
DOP2022000122A (es) 2022-07-31
CN114787183A (zh) 2022-07-22
PE20221518A1 (es) 2022-10-04
BR112022009396A2 (pt) 2022-08-09
AR120714A1 (es) 2022-03-09
AU2020408139B2 (en) 2024-03-28
ECSP22048612A (es) 2022-07-29
CL2022001623A1 (es) 2023-01-20
AU2020408139A1 (en) 2022-06-09
TWI795698B (zh) 2023-03-11
EP4077365A1 (en) 2022-10-26
IL293754A (en) 2022-08-01
MX2022007666A (es) 2022-07-19
JP2023506952A (ja) 2023-02-20
JOP20220153A1 (ar) 2023-01-30
WO2021126695A1 (en) 2021-06-24
CO2022008264A2 (es) 2022-07-08
CA3162245A1 (en) 2021-06-24
US20230102339A1 (en) 2023-03-30
KR20220100676A (ko) 2022-07-15
TW202138385A (zh) 2021-10-16

Similar Documents

Publication Publication Date Title
PH12020551025A1 (en) Incretin analogs and uses thereof
PH12020551024A1 (en) Incretin analogs and uses thereof
PH12021550154A1 (en) Gip/glp1 co-agonist compounds.
PH12017501252A1 (en) Gip and glp-1 co-agonist compounds.
JOP20220024A1 (ar) مركبات مساعدة لـ gipr
TN2017000148A1 (en) Co-agonists of the glucagon and glp-1 receptors
CR20220279A (es) Análogos de incretina y sus usos
EP4043026A4 (en) GLUCAGON, GLP-1 RECEPTOR AND DGIP RECEPTOR DUAL AGONIST COMPOSITION AND THERAPEUTIC USE THEREOF
EA202092891A1 (ru) Соединения-коагонисты gip/glp1
MX2021012177A (es) Usos terapeuticos de dulaglutida.